Latham & Watkins Advises RESILIENCE in its US$750 Million Series B Financing

A multidisciplinary team represents the newly launched life sciences company in the financing.

November 23, 2020

RESILIENCE (National Resilience, Inc.), a new company building the world's most advanced biopharmaceutical manufacturing ecosystem, announced its launch. RESILIENCE has raised over US$800 million of capital following the recent Series B raise of approximately US$750 million. Led by ARCH Venture Partners and 8VC with participation by GV and NEA, investors include public mutual funds, some of the largest U.S.-based pharmaceutical companies, foundations, family offices, and pension funds, among others.

Latham & Watkins LLP represents RESILIENCE in the transaction with a corporate deal team led by Bay Area partners Patrick Pohlen and Miles Jennings, with Bay Area associates Andrew Bertolli and Taimi Jacobson. Advice was also provided on antitrust matters by Washington, D.C. counsel Peter Todaro; and on regulatory matters by Washington, D.C. partners Steven Croley and Jim Barker. 


 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.